ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

infigratinib

Also written as “Infigratinib”, “BGJ398” and “infigratinib 0.128 mg/kg/day”.

Its studies are mostly in Achondroplasia · Mucopolysaccharidosis IV · Stomach Neoplasms · Cholangiocarcinoma · Urinary Bladder Neoplasms, led by 5 companies.

Drug pageInfigratinib: every studyMany companies study it; this page follows only the 17 they lead. All 30 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Dec 10, 201817 company-led studies, 3 open or runningNext primary completion: Jan 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BridgeBio83 open or runningphase 3since Dec 10, 2018May 12, 2014Jan 2027phase 3 · NCT06873035
Novartisits history only50 open or runningphase 2since Oct 28, 2013Oct 27, 2009none ahead
LianBioits history only20 open or runningphase 2since Jul 28, 2021Jul 28, 2021none ahead
Helsinn Healthcareits history only10 open or runningphase 2since Jan 12, 2022Jan 12, 2022none ahead
Pfizerits history only10 open or runningphase 2since Apr 28, 2014Apr 28, 2014none ahead

Also a collaborator on its studies: Labcorp Corporation of America.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of BridgeBio only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 12, 2014First study: phase 2 study in CholangiocarcinomaFirst studyNCT02150967 · 143 enrolled · United States, Belgium, Germany and more
  2. Dec 10, 2018Phase 3 study in CholangiocarcinomaNCT03773302 · 48 enrolled · United States, Australia, Belgium and more
  3. Dec 2, 2019Phase 3 study in Upper Tract Urothelial CarcinomasNCT04197986 · 39 enrolled · United States, Belgium, Bulgaria and more
  4. Jan 29, 2020Phase 2 study in AchondroplasiaNCT04265651 · 84 enrolled · United States, Australia, Canada and more
  5. Nov 22, 2021Phase 2 study in AchondroplasiaNCT05145010 · 325 planned · United States, Argentina, Australia and more
  6. Nov 29, 2023Phase 3 study in AchondroplasiaNCT06164951 · 114 enrolled · United States, Argentina, Australia and more
  7. Feb 18, 2025Phase 3 study in HypochondroplasiaNCT06873035 · 24 planned · United States, Australia, Canada and more
  8. Jan 19, 2026Phase 2 study in HypochondroplasiaNCT07393373 · 135 planned · United States, Australia, Canada and more

Ahead

  1. Jan 2027Primary completion: phase 3 study in HypochondroplasiaNCT06873035
  2. Dec 1, 2031Primary completion: phase 2 study in AchondroplasiaNCT05145010
  3. May 31, 2036Primary completion: phase 2 study in HypochondroplasiaNCT07393373

TargetBeta

“Fibroblast growth factor receptor inhibitor; Fibroblast growth factor receptor inhibitor”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
nintedanibruleBoehringer Ingelheimphase 476
futibatinibruleOtsukaphase 310

Studies

All 8 BridgeBio leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07393373Hypochondroplasia · United States, Australia, Canada and more2By invitationMay 31, 2036135
NCT06873035Hypochondroplasia · United States, Australia, Canada and more3By invitationJan 202724
NCT06164951Achondroplasia · United States, Argentina, Australia and more3CompletedDec 18, 2025114
NCT05145010Achondroplasia · United States, Argentina, Australia and more2By invitationDec 1, 2031325
NCT04265651Achondroplasia · United States, Australia, Canada and more2CompletedOct 21, 202484
NCT04197986Upper Tract Urothelial Carcinomas · United States, Belgium, Bulgaria and more3TerminatedFeb 28, 202339
NCT03773302Cholangiocarcinoma · United States, Australia, Belgium and more3TerminatedMar 2, 202348
NCT02150967Cholangiocarcinoma · United States, Belgium, Germany and more2TerminatedMar 1, 2021143

How it is read

Names in the registry

  • “Infigratinib”, 7 entries
  • “BGJ398”, 7 entries
  • “infigratinib 0.128 mg/kg/day”, 1 entry
  • “infigratinib 0.25 mg/kg/day”, 1 entry
  • “Infigratinib 0.25 mg/kg/day”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.